Actively Recruiting
Timing of Direct-Acting Antiviral Treatment in Kidney Transplant Recipients of Hepatitis C Virus-Positive Donor Kidneys A Randomized Controlled Trial
Led by Johns Hopkins University · Updated on 2026-09-04
120
Participants Needed
9
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the best timing to start medication for Hepatitis C Virus HCV in patients who receive HCV-positive kidneys but are themselves HCV-negative. This study compares two approaches to prevent or treat HCV infection in these kidney transplant recipients. The goal is to find out which timing strategy works better to manage HCV infection after transplant using a specific antiviral drug combination. The study evaluates the use of sofosbuvirvelpatasvir SOFVEL, a medication that stops HCV from multiplying. Participants are randomly assigned to one of two groups the prophylaxis group starts the medication before the transplant and takes it for 2 weeks, while the transmit-and-treat group begins the medication after the transplant and continues for 12 weeks. The shorter course before transplant and the longer course started post-transplant are both being studied to compare their effectiveness and safety. Participants will be closely monitored through the first 26 weeks after transplant to track liver injury, HCV infection outcomes, survival, and kidney graft function. Researchers will check blood tests, monitor for infections, graft rejection, and collect other health data at various points up to one year after transplant and beyond. This detailed follow-up helps assess the impact of the timing of antiviral treatment on transplant success and participant health.
CONDITIONS
Brief Title
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
Research Team
C
Christine Durand, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here